Movement Alert｜Exelixis Rises 5.54% in Regular Trading, Trading at $52.88

Market Focus05-29

On May 28, Exelixis rose 5.54% in regular trading, trading at $52.88 USD/share, with trading volume of $61.21 million.

Within the Biotechnology sector where Exelixis belongs, individual stock performance was mixed. Among individual stocks, AbbVie up 1.31%, Gilead Sciences up 1.06%, Natera up 1.03%, Regeneron Pharmaceuticals down 0.42%, Amgen down 0.38%.

Exelixis is an oncology-focused biotechnology company that discovers, develops, and commercializes new medicines for difficult-to-treat cancers. The company offers CABOMETYX and COMETRIQ derived from cabozantinib, and is advancing zanzalintinib, a next-generation oral tyrosine kinase inhibitor currently under FDA review for treatment of specific types of colorectal cancer.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1111683139?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-29 00:16","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1111683139","market":"hk","top_or_hot":-1,"title":"Movement Alert｜Exelixis Rises 5.54% in Regular Trading, Trading at $52.88","media":"Market Focus","content":"<p><p>On May 28, Exelixis rose 5.54% in regular trading, trading at $52.88 USD/share, with trading volume of $61.21 million.</p><p>Within the Biotechnology sector where Exelixis belongs, individual stock performance was mixed. Among individual stocks, AbbVie up 1.31%, Gilead Sciences up 1.06%, Natera up 1.03%, Regeneron Pharmaceuticals down 0.42%, Amgen down 0.38%.</p><p>Exelixis is an oncology-focused biotechnology company that discovers, develops, and commercializes new medicines for difficult-to-treat cancers. The company offers CABOMETYX and COMETRIQ derived from cabozantinib, and is advancing zanzalintinib, a next-generation oral tyrosine kinase inhibitor currently under FDA review for treatment of specific types of colorectal cancer.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜Exelixis Rises 5.54% in Regular Trading, Trading at $52.88</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜Exelixis Rises 5.54% in Regular Trading, Trading at $52.88\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-05-29 00:16</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On May 28, Exelixis rose 5.54% in regular trading, trading at $52.88 USD/share, with trading volume of $61.21 million.</p><p>Within the Biotechnology sector where Exelixis belongs, individual stock performance was mixed. Among individual stocks, AbbVie up 1.31%, Gilead Sciences up 1.06%, Natera up 1.03%, Regeneron Pharmaceuticals down 0.42%, Amgen down 0.38%.</p><p>Exelixis is an oncology-focused biotechnology company that discovers, develops, and commercializes new medicines for difficult-to-treat cancers. The company offers CABOMETYX and COMETRIQ derived from cabozantinib, and is advancing zanzalintinib, a next-generation oral tyrosine kinase inhibitor currently under FDA review for treatment of specific types of colorectal cancer.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"EXEL","symbol_name":"伊克力西斯","start_time":0,"source_url":"","article_id":"1111683139","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1111683139","pubTimestamp":1779984972,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On May 28, Exelixis rose 5.54% in regular trading, trading at $52.88 USD/share, with trading volume of $61.21 million.Within the Biotechnology sector where Exelixis belongs, individual stock...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"EXEL":"伊克力西斯"},"translate_title":"走势提示|Exelixis常规交易上涨5.54%，报52.88美元","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"EXEL":1},"content_text":"On May 28, Exelixis rose 5.54% in regular trading, trading at $52.88 USD/share, with trading volume of $61.21 million.Within the Biotechnology sector where Exelixis belongs, individual stock performance was mixed. Among individual stocks, AbbVie up 1.31%, Gilead Sciences up 1.06%, Natera up 1.03%, Regeneron Pharmaceuticals down 0.42%, Amgen down 0.38%.Exelixis is an oncology-focused biotechnology company that discovers, develops, and commercializes new medicines for difficult-to-treat cancers. The company offers CABOMETYX and COMETRIQ derived from cabozantinib, and is advancing zanzalintinib, a next-generation oral tyrosine kinase inhibitor currently under FDA review for treatment of specific types of colorectal cancer.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1111683139","isCrawlerRequest":true}